Publicacions en què col·labora amb Manuel Romero-Gómez (35)

2021

  1. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry

    Journal of Hepatology, Vol. 75, Núm. 1, pp. 86-97

  2. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects

    Liver International, Vol. 41, Núm. 9, pp. 2076-2086

2020

  1. Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5

  2. Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))

    Journal of Hepatology

  3. Programa poblacional de cribado de cáncer colorrectal. Documento de posicionamiento de la Sociedad Andaluza de Patología Digestiva. Requisitos mínimos para un cribado de calidad.

    Revista andaluza de patología digestiva, Vol. 43, Núm. 1, pp. 30-42

  4. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH

    Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25

2019

  1. Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH

    Gastroenterologia y Hepatologia, Vol. 42, Núm. 10, pp. 657-676

  2. Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort

    Journal of Viral Hepatitis, Vol. 26, Núm. 1, pp. 55-64

2018

  1. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline

    Gastroenterologia y Hepatologia, Vol. 41, Núm. 5, pp. 328-349

  2. Erratum to «Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline» [Gastroenterol Hepatol. 2018;41(5):328-349] (S0210570518300037) (10.1016/j.gastrohep.2017.12.003))

    Gastroenterologia y Hepatologia

  3. Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry

    Clinical Gastroenterology and Hepatology, Vol. 16, Núm. 9, pp. 1495-1502

  4. Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C

    Journal of Hepatology, Vol. 68, Núm. 5, pp. 940-948

  5. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity

    Alimentary Pharmacology and Therapeutics, Vol. 48, Núm. 11-12, pp. 1260-1270

2016

  1. Erratum: High-resolution hepatitis c virus subtyping using ns5b deep sequencing and phylogeny, an alternative to current methods (Journal of Clinical Microbiology (2015) 53:1 (219-226))

    Journal of Clinical Microbiology

2015

  1. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis

    World Journal of Gastroenterology, Vol. 21, Núm. 30, pp. 9163-9174

  2. Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection

    Genes and Immunity, Vol. 16, Núm. 5, pp. 297-300

  3. High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods

    Journal of Clinical Microbiology, Vol. 53, Núm. 1, pp. 219-226

2014

  1. Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study

    Gastroenterologia y Hepatologia, Vol. 37, Núm. 1, pp. 1-8

2011

  1. Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin

    American Journal of Gastroenterology, Vol. 106, Núm. 7, pp. 1246-1254

  2. La respuesta virológica al tratamiento con adefovir dipivoxil predice el desarrollo de resistencias a largo plazo en pacientes con hepatitis crónica B HBeAg negativo previamente no tratados

    Gastroenterologia y Hepatologia, Vol. 34, Núm. 2, pp. 69-74